The long-term goal of this project is to define the role that blood coagulation Factor XIII (FXIII) plays in stabilizing the hemostatic plug. The focus of this grant will be on the interaction between FXIII with fibrin and platelets in the hemostatic plug.
The specific aim are: (1) to localize and sequence the fibrin binding and platelet binding site(s) on the a-chain of FXIII; (2) to identify the Factor XIIIa binding site(is on fibrin and the platelet receptor for Factor XIIIA; (3) to study the physiologic consequences of inhibiting FXIII binding to fibrin and platelets in vitro. A method to purify the fibrin binding domain from a partial trypsin digest of platelet FXIII a-chains has been developed. A 54 kDa peptide contains the active site and has been purified to homogeneity and sequenced. An unlabeled 30 kDa polypeptide from the C-terminus of the molecule will also be purified. The effect of polyclonal affinity purified antibodies and monoclonal antibodies to the 54 kDa and 30 kDa polypeptides will be utilized to investigate whether they: modify thrombin cleavage of plasma FXIII, inhibit FXIII binding to fibrin, prevent FXIII crosslinking of fibrin, or enhance clot lysis in vitro. The effects of affinity purified antibodies will be investigated to determine whether they reduce FXIIIA crosslinking at the platelet surface, inhibit crosslinking of platelets to adhesive glycoproteins or inhibit plasmin degradation of platelet proteins. In addition, FXIIIa substrates on thrombin-stimulated platelets will be identified using [3h]-putrescine incorporation. Platelet glycoproteins IIb-IIIa has been identified as a Factor XIIIa receptor. Further characterization of the platelet receptor for Factor XIIIa will be obtained using flow cytometric analysis and photoaffinity crosslinking studies. cDNA clones from the a-chain of Factor XIII will be used to investigate whether the cloned proteins retains fibrin binding sites and to localize the binding site. Results from these studies may have direct application to the development of diagnostic and therapeutic agents which could benefit several thrombotic disorders including myocardial infraction, stroke and pulmonary embolization.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL038245-03
Application #
3354376
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1989-07-01
Project End
1994-06-30
Budget Start
1991-07-15
Budget End
1992-06-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Lai, T S; Hausladen, A; Slaughter, T F et al. (2001) Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40:4904-10
Blackwell, K L; Haroon, Z A; Shan, S et al. (2000) Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6:4359-64
Haroon, Z A; Raleigh, J A; Greenberg, C S et al. (2000) Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann Surg 231:137-47
Haroon, Z A; Lai, T S; Hettasch, J M et al. (1999) Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. Lab Invest 79:1679-86
Haroon, Z A; Hettasch, J M; Lai, T S et al. (1999) Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 13:1787-95
Lai, T S; Slaughter, T F; Peoples, K A et al. (1998) Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes. Identification of distinct binding sites for Mg-GTP and Mg-ATP. J Biol Chem 273:1776-81
Hettasch, J M; Peoples, K A; Greenberg, C S (1997) Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras. J Biol Chem 272:25149-56
Lai, T S; Bielawska, A; Peoples, K A et al. (1997) Sphingosylphosphocholine reduces the calcium ion requirement for activating tissue transglutaminase. J Biol Chem 272:16295-300
Lai, T S; Slaughter, T F; Koropchak, C M et al. (1996) C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity. J Biol Chem 271:31191-5
Lai, T S; Achyuthan, K E; Santiago, M A et al. (1994) Carboxyl-terminal truncation of recombinant factor XIII A-chains. Characterization of minimum structural requirement for transglutaminase activity. J Biol Chem 269:24596-601

Showing the most recent 10 out of 19 publications